Skip to content
Vaccibody becomes Nykode.
Read more
×
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
COVID trial
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
09/05/2022
Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer
06/05/2022
Nykode Therapeutics – Invitation to Capital Markets Day in Oslo on May 12, 2022
19/04/2022
Nykode Therapeutics to present at Kempen Life Sciences Conference
19/04/2022
Nykode Therapeutics to host Capital Markets Day
08/04/2022
Nykode Therapeutics announces presentation of preclinical data from its second generation Vaccibody vaccine technology at 2022 American Association for Cancer Research (AACR) Annual Meeting
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
